Oteseconazole Production Cost Reports

The report provides detailed analysis essential for establishing an oteseconazole production plant. It encompasses all critical aspects necessary for oteseconazole production, including the cost of oteseconazole production, oteseconazole plant cost, oteseconazole production costs, and the overall oteseconazole production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an oteseconazole production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Oteseconazole Market Analysis: Demand and Supply Analysis, and Sourcing

Oteseconazole is a tetrazole antifungal drug and the first drug approved for treating recurrent vulvovaginal candidiasis. It was developed by Viamet Pharmaceuticals through its metallophile chemistry program and later advanced by Mycovia Pharmaceuticals under the code VT-1161. Sold under the brand name Vivjoa, it treats a condition that affects millions of women and previously had no approved treatment. Fluconazole, itraconazole, boric acid, and topical azole medicines were commonly used off-label. Oteseconazole was developed to meet this treatment need. Doctors, health insurers, pharmacies, and specialty distributors handle it as a branded treatment course.

Oteseconazole supply depends on licensing agreements rather than an open market. Mycovia handles sales in the United States. Gedeon Richter markets and manufactures the drug in Europe, Latin America, Australia, Russia, and other CIS countries. Jiangsu Hengrui Medicine holds the rights to the oral capsule in Greater China. The active ingredient is supplied by a small group of specialist chemical manufacturers. Dynamit Nobel in Germany, Apino Pharma in China, and Veeprho in the Czech Republic all offer the material. An oteseconazole demand and supply analysis considers its limited approved use, single dosage form, patent protection until 2031, and the availability of facilities that can handle azide chemistry. Only a few plants have the required production capabilities. Freight, cold storage, product serialization, tender listing, and local registration requirements affect each regional launch.

Oteseconazole demand depends on its approved use rather than the total number of people with the condition. It is approved only for females who cannot become pregnant, including postmenopausal patients and those who have had tubal ligation, hysterectomy, or other procedures that permanently prevent pregnancy. This restriction is linked to its long terminal half-life of around 138 days, meaning the drug can remain in the body for roughly 690 days. Each patient takes a specific treatment course rather than using the drug continuously. As a result, sales volumes remain low, and prices stay high. Demand forecasts depend more on how many doctors prescribe the drug than on the number of people with the condition. Capsule count, treatment duration, refill timing, and patient adherence all affect demand estimates.

Summary of the Product, Grades, and Uses

Oteseconazole has CAS number 1340593-59-0, the molecular formula C23H16F7N5O2, and a molecular weight of 527.4 g/mol. Its ATC code is J02AC06. Its structure contains a difluorophenyl ring, a difluoromethylene bridge, a tetrazole ring, and a trifluoroethoxyphenyl pyridine group around a chiral tertiary alcohol. The drug is a white to off-white crystalline powder that is almost insoluble in water across the pH range of 1 to 9 but dissolves in several organic solvents. The molecule contains seven fluorine atoms, which is unusual even among modern antifungal drugs. This high fluorine content affects both the manufacturing process and raw material costs. Quality tests check assay, chiral purity, related substances, residual solvents, and elemental impurities.

Oteseconazole differs from every marketed azole in one structural detail. Older agents carry a triazole that binds the heme iron of fungal CYP51, while this molecule carries a tetrazole in the same position. The tetrazole binds fungal CYP51 tightly and human CYP enzymes far less, which is what gives the selectivity the program was designed around. Chirality matters just as much, since only the 2R configuration carries activity. Chiral purity above 99 percent is therefore a release requirement rather than a preference. Polarimetry, chiral chromatography, diffraction, and spectroscopy all feed that identity package.

Oteseconazole reaches the market in one dosage form, a 150 mg oral capsule. The formulation uses croscarmellose sodium, hydroxypropyl cellulose, lactose, magnesium stearate, silicified microcrystalline cellulose, and sodium lauryl sulfate, inside a gelatin shell colored with titanium dioxide and permitted dyes. Active ingredient grade, impurity reference standards, labeled analogs, and metabolite standards make up the material types in commercial circulation. A phosphate disodium salt prodrug has also been prepared and crystallized, since the parent molecule suits solid forms far better than liquid ones. Tablets, suspensions, topical forms, and intravenous solutions all remain out of reach for the free base.

Main End-Uses of Oteseconazole

Oteseconazole is prescribed for one labeled indication, which is reduction of recurrent vulvovaginal candidiasis in females with a history of the condition. Two regimens appear on the label. The first runs 600 mg on day one, 450 mg on day two, then 150 mg once weekly from day fourteen for eleven weeks. The second starts with fluconazole 150 mg on days one, four & seven. Oteseconazole then runs at 150 mg daily from day fourteen through day twenty, then 150 mg weekly from day twenty-eight for eleven weeks. Capsules are swallowed whole with food. Food effect, timing, adherence, storage, and patient counseling all sit in the dispensing instructions.

Oteseconazole has been studied well beyond that single label. Onychomycosis reached phase two, where the long half-life and nail keratin binding both work in the drug's favor. Tinea pedis, invasive fungal infection, dermatophyte nail disease, and other targets appear in the broader development picture. The Greater China license covers recurrent vulvovaginal candidiasis, onychomycosis, and invasive fungal infections together, which signals where the licensee expects the molecule to go. Each new indication would lift volume well above the current base. Nail, skin, mucosal, and systemic targets each carry their own dose, duration and trial cost.

Oteseconazole also has a steady market for analytical testing and research. Laboratories buy impurity standards, metabolite standards, system suitability mixtures, and labeled versions of the compound in milligram quantities for method validation. Microbiology researchers use it to test its activity against Candida and Cryptococcus species. Formulation developers buy small quantities for dissolution and stability studies. These uses require very little material, but the same chemical production process is needed. Each order includes milligram-sized vials, certificates of analysis, structural data, and stability records.

Oteseconazole Market Risks

Oteseconazole has a commercial risk because it stays in the body for a long time. Its terminal half-life is around 138 days, meaning the drug can remain in the body for close to two years after the last dose. Therefore, it is not approved for females who can become pregnant. Other reasons to avoid the drug include pregnancy, breastfeeding, plans to breastfeed, and known hypersensitivity to the medicine. These restrictions greatly reduce the number of eligible patients, as the condition mainly affects younger women. Any expansion of its approved use would require new reproductive toxicity data. Product labeling, patient counseling, pregnancy testing, doctor education, and pharmacy checks must all follow these restrictions.

Oteseconazole also faces competition from very cheap medicines. Generic fluconazole costs only a few cents per tablet, is widely available, and is familiar to doctors, even though it is used off-label for this condition. Health insurers may resist paying for a branded treatment when a low-cost generic is commonly used. Patent protection lasts until 2031, giving the product a limited commercial window. Manufacturing also carries a risk because the azide reaction takes place at a single qualified plant. An incident at that plant could stop the supply completely. Regular audits, insurance, a second supplier, backup stock, and careful production scheduling help manage these risks.

Oteseconazole Production Process and Main Cost Drivers

The oteseconazole production process runs from 2,5-dibromopyridine and ethyl bromodifluoroacetate through copper-mediated coupling, ketone formation, an asymmetric Henry reaction, nitro reduction, classical resolution, Suzuki coupling, tetrazole formation, crystallization, and drying.

1. By Asymmetric Henry Reaction, Tartrate Resolution and Azide Tetrazole Formation: The main inputs are 2,5-dibromopyridine, ethyl bromodifluoroacetate, copper powder, 1-bromo-2,4-difluorobenzene, nitromethane, a chiral alkaloid catalyst, platinum and palladium catalysts, di-p-toluoyl L-tartaric acid, a boronic acid, trimethylsilyl azide, and solvents.

Oteseconazole synthesis begins with the difluorinated ester. Ethyl bromodifluoroacetate, stoichiometric copper powder, and 2,5-dibromopyridine react in dimethyl sulfoxide to give that ester, which is purified by distillation. The ketone follows, either by direct addition of the lithiated aryl bromide from 1-bromo-2,4-difluorobenzene and n-butyllithium in methyl tert-butyl ether, or through a morpholine amide and a Grignard reagent. The ketone is an oil and goes forward without purification. Early discovery work installed the tetrazole using diazomethane, which no plant would run at scale. The asymmetric route exists to avoid that reagent entirely. Scale, safety, cost, throughput, and regulatory acceptance all pushed the program that way.

Oteseconazole stereochemistry is set in the middle of the sequence. Nitromethane adds to the ketone under a cinchona alkaloid catalyst in an asymmetric Henry reaction. That step gives the tertiary alcohol in 75 percent yield, at roughly a 90: 10 enantiomer ratio. Platinum-catalyzed hydrogenation then reduces the nitro group to the primary amine. Classical resolution with di-p-toluoyl L-tartaric acid lifts chiral purity above 99 percent, at 33 percent yield, which is where most of the material is lost. Suzuki coupling with the trifluoroethoxyphenyl boronic acid builds the biaryl, isolated as the tartrate salt. Trimethylsilyl azide in acetic acid, with sodium acetate and trimethyl orthoformate, then closes the tetrazole ring. A palladium scavenger strips residual metal. Crystallization from ethanol and water, after potassium carbonate adjustment, gives the hydrate at 85 percent. Recrystallization from ethanol & n-heptane delivers the anhydrous form at 90 percent. Particle size, polymorph, residual solvent, water content, and bulk density are set at that stage.

Main Factors Affecting Oteseconazole Production Cost

Oteseconazole production costs mainly depend on material losses during the middle stages of manufacturing. The tartrate resolution step recovers only 33% of the material entering it, meaning about two-thirds of the material used in earlier stages is lost at this point. The costs of 2,5-dibromopyridine, ethyl bromodifluoroacetate, copper, and aryl bromide used before this step are therefore spread across only one-third of the output. Improving the asymmetric reaction or recycling the unwanted enantiomer would have a greater effect on costs than changes in purchasing. The 90:10 enantiomer ratio produced by the Henry reaction limits the amount of desired material that can be recovered during resolution. Catalyst loading, temperature, solvent choice, addition rate, and aging time all affect this ratio.

Oteseconazole cost is also shaped by hazard and by metals. Trimethylsilyl azide brings hydrazoic acid risk, so the tetrazole step needs blast protection, calorimetry data, dedicated quench systems & trained operators. That infrastructure is why only a handful of plants bid for the work. Palladium from the Suzuki coupling has to come out to pharmaceutical limits, which costs a scavenger pass and an analytical burden. Platinum hydrogenation, the cinchona alkaloid catalyst, the boronic acid & chiral tartaric acid are all expensive inputs in their own right. Low annual volume spreads all of this across very few kilograms. Metal recovery, solvent recycling, mother liquor rework & scavenger reuse claw back part of it.

Raw Materials for Oteseconazole Production Plant and its Procurement

Oteseconazole raw material procurement is specialized, fluorine-heavy, slow to qualify & tightly controlled. Ethyl bromodifluoroacetate and 1-bromo-2,4-difluorobenzene come from fluorochemical houses rather than from commodity suppliers. 2,5-Dibromopyridine, the trifluoroethoxyphenyl boronic acid & the cinchona alkaloid catalyst each come from a short list of fine chemical makers. Trimethylsilyl azide is sold under controlled conditions by a small number of producers. Copper powder, nitromethane, acetic acid, sodium acetate & trimethyl orthoformate are the ordinary purchases on the list. Lead times, minimum order quantities, transport rules & shelf life govern how each is bought.

Oteseconazole plants hold inventory because the chain is thin. A single supplier failure on the boronic acid or the azide reagent stops the campaign, so buyers qualify second sources where they can and stock ahead where they cannot. Platinum and palladium are bought or leased against metal prices, with assay, return terms & recovery contracts on the spent catalyst. Each incoming lot is tested for identity, assay, water, isomer content & metal residues before release. Solvent grades matter too, since dimethyl sulfoxide, methyl tert-butyl ether, ethanol & n-heptane all carry through to residual solvent limits. Water content, peroxide value, assay & color are checked on every solvent drum.

Sustainability and Regulatory Requirements

Oteseconazole manufacture runs under full pharmaceutical good manufacturing practice with no pharmacopoeial monograph to fall back on. Specifications come from the new drug application file instead, covering assay, chiral purity, related substances, residual solvents, elemental impurities & water content. Chiral purity above 99 percent and palladium below the permitted daily exposure limit are the two defining tests. Process safety documentation for the azide step sits alongside the quality file and is examined just as closely. Any change to that step reopens both the safety case and the regulatory submission. Batch records, deviations, change control, annual review & inspection readiness run alongside.

Oteseconazole waste streams need handling that an ordinary synthesis plant is not built for. Azide-bearing liquors are quenched chemically before they reach any acidic drain, since hydrazoic acid forms readily and is both toxic and explosive. Fluorinated byproducts resist biological treatment, so aqueous streams go to incineration rather than to a conventional effluent plant. Spent platinum and palladium catalysts are collected and refined for metal recovery. Dimethyl sulfoxide, methyl tert-butyl ether, ethanol & heptane are recovered by distillation where volumes justify the still. Energy, water, solvent loss & hazardous waste tonnage are tracked campaign by campaign.

CAPEX and OPEX for an Oteseconazole Production Plant

The oteseconazole plant setup cost reflects hazard containment rather than tonnage. Glass-lined and stainless reactors in the hundreds of liters cover the coupling, Henry reaction, hydrogenation & resolution steps, with a dedicated bay for the azide chemistry behind blast walls. A hydrogenation suite with its own pressure rating, nitrogen inerting, oxygen monitoring & relief systems sits apart from the rest. Downstream equipment covers filter dryers, crystallizers, a solvent recovery train, milling & controlled packing. Analytical capability has to include chiral chromatography, inductively coupled plasma for metals, headspace gas chromatography & calorimetry for process safety work.

Oteseconazole operating costs mainly come from raw materials and regulatory requirements, rather than labor or utilities. Fluorinated raw materials, precious metal catalysts, the azide reagent, and the chiral resolving agent make up a large share of material costs. Quality control, stability testing, process safety reviews, and regulatory maintenance also account for a major part of the expenses. Production campaigns are short, so cleaning and checking equipment between batches reduces the time available for production. Equipment depreciation per kilogram is high because the plant has a large amount of equipment compared with its output. The plant must be used efficiently for production to remain profitable. Other fixed costs include insurance, calibration, maintenance, environmental monitoring, and waste disposal.

Plant Location and Investment Factors

Oteseconazole production is concentrated in regions that already have facilities for azide and fluorine chemistry. Germany has strong expertise in azide and energetic chemistry through its explosives and fine chemical industries, making it suitable for the tetrazole production stage. India and China have large fluorochemical industries with lower production costs and growing experience in chiral synthesis. The United States and Europe offer the regulatory experience needed to support a new branded drug. Plant location depends first on technical capabilities and then on cost. Permits, explosion safety standards, trained workers, testing facilities, and inspection records help determine which sites are suitable.

Investment decisions for oteseconazole depend on whether production facilities are dedicated to the drug or shared with other products. A dedicated plant may remain unused between production campaigns because annual demand can be met in just a few runs. A shared multipurpose facility with a separate area designed for hazardous reactions can spread fixed costs across several products. Licensing is another option, and the drug follows this model, with regional partners handling manufacturing and sales. Contract manufacturing by a specialist with existing azide facilities can also avoid the need for major capital investment. Production transfer documents, process safety data, analytical methods, and reference standards are shared with the manufacturing partner.

Major Oteseconazole Producing Regions

Oteseconazole production and supply are spread across North America, Europe, and Asia, with each region serving a different purpose. The United States is home to the original developer and the approved product through Mycovia Pharmaceuticals. Germany provides active ingredient manufacturing capabilities, as its experience in azide and energetic chemistry is well suited to the tetrazole production stage. Hungary holds European manufacturing and commercial rights through Gedeon Richter, with rights also covering Latin America, Australia, Russia, and the CIS. China holds rights for Greater China through Jiangsu Hengrui Medicine and supplies research-scale material through specialist chemical manufacturers. The Czech Republic and India supply impurity standards, metabolite standards, labelled analogues, and analytical reference materials.

Key Oteseconazole Producers

Mycovia Pharmaceuticals

• United States developer that carried the molecule from Viamet Pharmaceuticals through to approval.
• Markets the 150 mg capsule as Vivjoa for recurrent vulvovaginal candidiasis.
• Competes on first approval in the indication, clinical data, prescriber education, patent position & label exclusivity.
• Holds compound protection running to 2031 across the United States and Europe.

Gedeon Richter

• Hungarian pharmaceutical group with a long women's health franchise.
• Licensed to commercialize and manufacture the product across Europe, Latin America, Australia, Russia & other CIS countries.
• Competes on regional reach, women's health specialization, manufacturing depth & technology transfer capability.
• Took the license with a development and technology transfer component attached.

Jiangsu Hengrui Medicine

• Chinese pharmaceutical company holding Greater China rights to the oral capsule.
• Covers recurrent vulvovaginal candidiasis, onychomycosis & invasive fungal infections under that license.
• Competes on domestic development capability, regulatory experience, trial infrastructure, scale & commercial reach.
• Runs its own research and manufacturing base for small molecule drugs.

Dynamit Nobel

• German chemical producer with roots in energetic and azide chemistry.
• Offers oteseconazole active ingredient under good manufacturing practice with regulatory coverage.
• Competes on hazardous chemistry capability, containment infrastructure, process safety data, documentation & safety record.
• Brings exactly the azide handling expertise the tetrazole-forming step demands.

Veeprho Group

• Czech supplier of active ingredients, impurities & analytical reference materials.
• Produces oteseconazole and related reference compounds for development and testing work.
• Competes on small-lot flexibility, characterization data, purity, turnaround & catalog breadth.
• Serves method validation and stability programs rather than commercial supply.

Apino Pharma

• Chinese producer offering oteseconazole active ingredient to development customers.
• Supplies material with certificates of analysis for research and formulation work.
• Competes on cost base, responsiveness, small quantities, pricing & willingness for custom synthesis.
• Sits alongside the impurity and metabolite suppliers in the development supply chain.